Print
Advertisement
Japan's MHLW grants orphan drug designation to treatments designed for fewer than 50,000 patients.
The retrospective, observational study included adults who received their first allogeneic HSCT during their first remission.
Dr. Coombs discusses her journey into oncology, what it’s like to broach the lymphoid and myeloid worlds, and a unique ...
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Othman Al-Sawaf, MD, and Nicole Lamanna, MD, debate approaches in this Point | Counterpoint.
September is always an exciting time for SOHO members as the month brings the Annual Meeting in Houston, Texas.
Advertisement
Critical drugs used to treat cancer are in short supply in the United States and around the globe.
Single-cell analysis has shed new light on the unique biology of classic Hodgkin lymphoma (HL).
Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches."
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
The Blood Cancers Today Editorial Board reflects on the latest news in the field so far in 2023.
SOHO President Jennifer Brown, MD, PhD, reflects on the upcoming 11th SOHO Annual Meeting.
An open-label phase I study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AVC-201.
It is approved as a weekly or biweekly subcutaneous injection after an initial step-up phase.
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
Guillermo Garcia-Manero, MD, the 2023 SOHO President-Elect, shares his hopes and goals for the coming years.
The application for the approval of epcoritamab is based on results from the phase I/II EPCORE NHL-1 trial.
EMA CHMP adopted a positive opinion recommending the marketing authorization of JZP458.
Key advances in understanding and detecting ctDNA could usher in a future with less invasive, but more informative biopsies.
The “effect of gilteritinib was more pronounced” in patients who had detectable MRD than those who did not.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.